Value of real-world insights in ophthalmology and GA treatment

Data can clear a path to trends and strategies to meet patients’ needs

Data are powerful. With the ability to gather large data sets more accurately and easily for analysis, researchers can discover trends in the general health of the population and how subpopulations are—or are not—having their needs met. These analyses can empower better treatment and even motivate additional treatment options or strategies to fill the gaps in treatment needs.

Related to this article

July 7th, 2026

FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease

The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.

June 30th, 2026

From detection to decision-making: Navigating disease progression and treatment in geographic atrophy

Three real-world cases illustrate strategies to identify and manage GA across a range of scenarios, from coexisting wet age-related macular degeneration to functionally monocular patients.

June 27th, 2026

Lesion growth rate reduction tops retina specialists' geographic atrophy treatment priorities

In a preference study, Csaky and colleagues found that lesion growth rate reduction was the primary driver of GA treatment decisions among US retina specialists, with greater risk tolerance for foveal-threatening lesions.

July 30th, 2026

Frantz EyeCare LAL outcomes exceed national benchmarks in single-center cataract data

Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.

July 23rd, 2026

Emerging dry eye therapies and co-managing MGD: Ping Moore, OD

In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.